The US biotech company, focusing om messenger RNA therapeutics and vaccines, has announced plans to expand its commercial footprint in Europe across six additional countries. The announcement reinforces Moderna’s commitment
Nordic Life Science
Pharma news from the Nordic life science industry
Latest news
BioArctic has announced that the company’s partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805. BioArctic and AbbVie have collaborated since
Ilya Pharma has made a strategic investment in its supply chain to facilitate development of its ILP pipeline by acquiring one of its long-term partners, Nordic Bioanalysis. Founded in 2010,
The company is carrying out a set-off issue of 845,070 shares to Acturum Life AB as a result of a previously agreed milestone payment, which will be made in the
The Board of Directors of Moberg Pharma has resolved to carry out a fully guaranteed issue of new ordinary shares with preferential rights for existing shareholders of approximately SEK 121
Sobi has announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF/Xyntha (ReFacto) has been amended due to clarity of final order volumes and will
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved a 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for
InDex Pharmaceuticals Holding is planning for self-commercialization of the drug candidate cobitolimod in the US with strategic collaborations in other regions. Launch is expected in 2027, with the potential for
Finnish DelSiTech and Swiss-based Optifye Therapeutics have announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech Silica Matrix technology. Controlled release of dexamethasone
Ondexxya has been approved in Japan for patients treated with the Factor Xa (FXa) inhibitors apixaban, rivaroxaban or edoxaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled
The company has secured a private placement, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development
Clinical trials
LINK Medical is currently preparing to work in line with the Clinical Trial Regulation, going into effect on the 31st of January 2022. The new regulation will replace the Clinical
Bavarian Nordic has announced the dosing of the first subject in the Phase 3 VANIR clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV in older
Genmab and AbbVie have announced topline results from the first cohort of the EPCORE NHL-1 clinical trial evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157
Lundbeck recently completed a global Phase IV, randomized, comparative study exploring the role of vortioxetine as a treatment option between SSRIs and serotonin–noradrenaline reuptake inhibitors (SNRIs). The efficacy of vortioxetine
Elypta has announced the launch of its second clinical study intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for
TILT Biotherapeutics has announced positive interim progress and safety data from its phase 1 clinical trials in metastatic melanoma (T215 – the ‘TUNINTIL’ trial) and solid tumors (T115 – the
Atrogi has received approval from the German authority BfArM to initiate a phase 1 study with their small molecule drug candidate ATR-258 in healthy volunteers and type 2 diabetics. The
Vicore Pharma Holding has announced plans to initiate a clinical trial with C21 in Pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a rare lung disease with huge unmet medical
The CALLA Phase III trial for AstraZeneca’s Imfinzi given concurrently with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of improving progression-free survival (PFS) versus CRT alone
Sustainability
A new study by an international consortium, including researchers from Stockholm University, looking at the presence of pharmaceuticals in the world’s rivers, found concentrations at potentially toxic levels in more
CDMO Recipharm has announced that its 2020 International Environmental Award will be presented to Amy Pruden, Professor of Civil and Environmental Engineering at Virginia Tech in Blacksburg, Virginia, US. Amy
The professorship at the University of Helsinki, which is being established with the support of a fund, is aimed at strengthening sustainable development expertise in pharmacy across the globe. The
IVL Swedish Environmental Research Institute and Simrishamn Municipality have tested a completley new treatment system that has now been added to the Stengården sewage plant in Simrishamn, Sweden. “Removing pharmaceutical
Nordic efforts to prevent pharmaceuticals affecting the environment include Danish management of hospital wastewater and a Swedish large-scale sewage plant for removal of pharmaceutical residues. Wastewater from hospitals can contain